This year has brought many exciting achievements for M2D2 resident companies—and here’s one more. Glyscend, a polymer therapeutics company focused on revolutionizing Type 2 diabetes treatment, has been named one of two startup labs selected to receive funding from Breakout Labs. Glyscend operates facilities at both M2D2 in Lowell and at the Johns Hopkins Fast Forward facility in Baltimore.Continue reading
This spring UMass Lowell Department of Chemical Engineering, and the UML’s Massachusetts Biomanufacturing Center received funding through the Massachusetts Life Science Center “Building Breakthroughs” program. The funding will support continuous bioprocessing manufacturing as an alternative to batch manufacturing. This new process is being explored in the manufacturing of small molecule drugs by the pharmaceutical industry. The research grant is part of a consortium that includes the M2D2 resident company (and 2018 $200K Challenge finalist) Versatope Therapeutics, who have developed an exosome-like vesicle technology currently used for vaccines. With this funding, these organizations are creating a truly transformative “continuous manufacturing” process for biopharmaceutical manufacturing. Continue reading
We’re thrilled to spread the word that one of our innovative resident companies, LivOnyx, has been named one of five 2019 winners in the Massachusetts Life Sciences Center (MSLC) Massachusetts Next Generation Initiative. LivOnyx will receive $87,500 in funding, as well as access for a year to a network of executive coaches.Continue reading
The BARDA DRIVe team is pleased to announce that the new, easy-to-use EZ BAA online Portal is now live as of April 23, 2019. This Portal will replace the existing PDF-based process, helping to improve the user experience, data integrity, and data security. The system will also streamline internal processes, helping DRIVe’s program teams continue to make awards in as few as 30 days.
With support from the Deshpande Foundation, three finalist startups from an incubator in Chennai, India were able to pitch their life sciences innovations in Lowell on March 27. Not only did they compete, but they were also able to immerse themselves first-hand in the burgeoning biotech ecosystem that’s making Boston and environs the talk of the innovation economy.Continue reading
Dynocardia is 1 of 19 finalists chosen to pitch at the $200K Challenge Pitch-Off last Wednesday. Dynocardia’s ViTrack™ is the first-of-its-kind, standalone, cuff-less, wearable device for continuous non-invasive blood pressure monitoring.
Mohan Thanikachalam, CEO of Dynocardia, offers us an exclusive inside look behind the development of the ViTrackTM!Read more
V. Kadir Kadhiresan,
PhD – Vice President, Venture Investments at Johnson & Johnson
We’re thrilled to welcome Johnson & Johnson Innovation’s V. Kadir Kadhiresan as the keynote speaker for the $200K Challenge Award Celebration on 4/10 in Boston!Continue reading
On Wednesday night, nearly 250 attendees—life sciences innovators, investors, researchers, academics, and students—gatheredin UMass Lowell’s Maloney hall for the 2019 M2D2 $200K Challenge Pitch-Off.Continue reading
BuzzArk Simulations, chosen for their development of a VR simulation for natural orifice surgery procedures, is 1 of 20 MedTech startup finalists in the 8th annual M2D2 $200K Challenge.
Ragul Puhazhendi, Founder of Buzzark, offers us an exclusive inside look at the ups and downs behind the development of their simulation technology.